Clinically, plasma Tgfβ1 levels correlated positively with the MO-MDSC/PMN-MDSC ratio across multiple cancer types including CRC, ovarian cancer, and breast cancer, suggesting its potential as a biomarker for stratifying the MO-MDSC/PMN-MDSC ratio in cancer patients. Here, TGFB1 is linked to breast carcinoma.